we start with eli lilly. since 1996, eli increased the price of you know log 34 times from $21 to 200 and $75 -- $275. i'm told it cost five dollars to manufacture this product. the story is not different or products produced by senovi. my question to you and other companies, we commit to this committee today that you will not increase the price of any insulin product again? >> thank you. as has been mentioned, we have not increase prices since i have been ceo. i'm comfortable saying we will leave our prices as they are. >> on all of our markets? >> we have been cutting them. >> we have said before, we have a responsible and sustainable pricing approach. net prices continue to fall in the net price is lower than it was when it was launched in 2001. >> i'm hearing from you the you the will not increase the price for any insulin product again? >> to repeat myself -- >> yes or no will be the better answer. >> we have a responsible price listing. >> thank you. we have committed to limiting potential price increase

eli lilly is the only company authorized by regulators to sell drugs containing this substance. it also recently got approval to start selling in the u.k. youtube has suspended british comedian russell brand from making money on the platform following allegations of sexual assault. and found fame -- brand found fame on mainstream media but has since pivoted away from tv to focus on standup comedy shows and social media. his youtube has 6.6 one million subscribers. the platform says it cut him off from advertising revenue to protect his community. >> there is a template that. it depends on how successful his legal proceedings are. if he still makes money for people, people will put him on because the kind of misogyny in his material is very much present on the circuit anyway. >> the u.s. securities and exchange commission has charged a new york-based firm and its owner for failing to register with regulators while acting as an investment advisor to a russian billionaire. in a court filing, the sec said the company and its owner sourced, arranged, and monitored hundreds of investm

i mean, i know eli lilly basically their runup is based on their medicine pipeline, but anything with extended run, protect long stop populasitions makes sense. >> is tost is good call spread opportunitisome. >> it feels risky to get long something called tost. but this has high options premiums and deservedly so. they're reporting earnings in november, a company a lot of people are expecting to turn profitable and it's really going to move around. i think call spreads are the way to make long bets rather than buying. >> carter has been correctly calling a bearish to bullish reversal in oil prices past two months, does he see the same for ung? >> given we're going to back away from oil i would point out that christmas net gas contracts made new 52-week lows today, hold off on ung here. >> mike, is that -- i mean, if we think that oil is going to pull back, or stall, how about xle? >>. >> yeah, so we were long xle, i think now might be a good time to take some profits if you are in that call spread. >> all right, it is time now for the final call. on the options pit. carter braxton wor

our first fan asks, eli lilly has been recently overbought after touching 600. it ripe for a mean reversion trade when at the money 580, 560, bear put spread be a good options play here, brian, what do you say? >> yeah, it's not a bad trade. i mean, i know eli lilly basically their runup is based on their medicine pipeline, but anything with an extended run, to the upside this year, we could see volatility. buying put spreads to protect long stop positions makes sense. >> is tost a good call spread opportunity? >> it feels risky to get long something called tost. but this has high options premiums and deservedly so. they're reporting earnings in november, a company a lot of people are expecting to turn profitable and it's really going to move around. i think call spreads are the way to make long bets rather than buying. >> look at that. we have time for one more question. carter has been correctly calling a bearish to bullish reversal in oil prices past two months, does he see the same for ung? what's your take? >> given we're going to back away from oil i would

our first fan asks, eli lilly has recently been overbought.sion trade. 580/560, bear put spread be a good options play here? brian, what do you say? >> it's not a bad trade. i know eli lilly, their run-up is based on their medicine pipeline. anything that's had an extended run, we could see it in the coming weeks. it makes a lot of sense. >>> is toast a good call spread opportunity? mike? >> it always feels a bit risky to get long something called tost. it has very high options premiums and deservedly so. this thing moves. this is a company that a lot of people are expecting to turn profitable and it's really going to move around. i think call spreads are the way to make your long bets rather than buying the underlying. >> we have time for one more question. carter has been correctly calling a berish to bullish reversal for the past two months. does he see the same for the ung? >> given that we're going to want to back away for oil here, i would point out that christmas nat gas contracts made new 52-week lows. i would hold on. >> mike, if we t

. >> eli lilly, the maker of the maker company of manjaro, has filed lawsuits against ten medical spas, wellness clinics and pharmacies for allegedly selling knockoff drugs. the suit claims these places market and sell products that are not fda approved and fraudulently claim to be their drug. most of the lawsuits claim misuse of their trademark to the original manjaro is approved to treat type two diabetes, and the fda warns that off brand weight loss drugs they can be unsafe. eli lilly seeks to block sales of what they consider counterfeit versions of their drug and receive financial damages. >> new at 11 united airlines is making use of its brand new electric super tugs. these machines can move airplanes across tarmacs and runways without burning any jet fuel. lax's first airport to use these emission free, battery powered tugs can last up to nine hours on a single charge. >> this is this is not all, you know, united's also invested in electric airplanes. we have a regional jet coming in 2026. we've also invested in electric flying taxis. also has invested in hydrogen powered jet en

its life sciences business has long times to eli lilly and novo nordisk.. thank you for seeing us here on-set. >> thank you for having me. >> it's 60% -- >> it is. >> life sciences. >> it is. we entered the life sciences world almost 75 years ago. our founder, dr. jacobs, actually right here in brooklyn, was a merck employee and left merck to start his own engineering firm and it -- and merck hatz bs been a long-stand client since then. >> so, we mentioned you're long-standing ties to novo and eli lilly, the manufacturers of glp-1s. so, how are you thinking about what that adds to your pipeline, which had been at about 27 billion at the end of fiscal full year 2022? >> correct. correct. if you think about the life sciences business, in the last five years, driven by two other verticals, oncology drugs, as well as alzheimer's, all the advancements that are happening there, we've doubled the size of our business in the last five years. along with chip manufacturing, as well. so, that business has been on a growth train driven by technology advancements and t

eli lilly hit another all-time high today. for more, let's bring in jared holz.t to have you with us. >> great to see you, thank you. >> you know, it seems like these drugs, glp-1s, they could be the cure-all for not just, you know, obesity, but for diabetes potentially, entirely, in terms of eliminating the use or need for insulin, in terms of addictions of all sorts, in terms of alzheimer's, in terms of sleep apnea. so, why should we be skeptical when a note says $100 billion eventually? it's the cure-all drug, it seems. >> i mean, maybe we shouldn't be at this point. i think the -- the reason to be skeptical probably comes down to a couple of things. it comes down to, you know, how big of a target these drugs wind up being for payers, the manage care companies and how they kind of navigate the next several years from a demand standpoint and from a pricing standpoint and an access standpoint. that would probably be, you know, maybe the biggest deterrent. and then, the second is just pricing longer term. but if these drugs are really cure-alls like, you know, we

. >> eli lilly, the maker of the maker company of manjaro, has filed lawsuits against ten medical spascs and pharmacies for allegedly selling knockoff drugs. the suit claims these places market and sell products that are not fda approved and fraudulently claim to be their drug. most of the lawsuits claim misuse of their trademark to the original manjaro is approved to treat type two diabetes, and the fda warns that off brand weight loss drugs they can be unsafe. eli lilly seeks to block sales of what they consider counterfeit versions of their drug and receive financial damages. >> new at 11 united airlines is making use of its brand new electric super tugs. these machines can move airplanes across tarmacs and runways without burning any jet fuel. lax's first airport to use these emission free, battery powered tugs can last up to nine hours on a single charge. >> this is this is not all, you know, united's also invested in electric airplanes. we have a regional jet coming in 2026. we've also invested in electric flying taxis. also has invested in hydrogen powered jet engine. >> the com

analysts saying that structure's pill could be kpi we lie lilly's pill, and eli lilly being a growingin the space. it's important to know this is a tiny trial and results are early. the study included only 24 people and findings will need to be confirmed in future studies. >> and this is a pill form, correct? >> reporter: correct. >> tim, you're pointing out novo and eli lilly have had a pullback. >> lilly's down 11% from what looks like a blow-off top on volume and traded down to the 50. this is not cause for alarm if you're a bull. what's cause for at least review is the competitive landscape. it is getting -- i think it's less about the sum of the regulatory concerns that might be coming with some of these studies that are proving all kinds of side effects that aren't great. i think it's the competitive landscape. the question really is about total adjustable market and margin expansion. those are things analysts have had a good time with lilly doing whatever they want. 78 times trailing tells you where the stock needs to go in the future. >> right, and the irony is of course the w

stuart: eli lilly makes a very popular weight loss drug. clarification would be it's a diabetes drug that people use for weight loss. they're suing ten clinics, spas, wellness centers for trademark infringement by sharing the fake version. so they used one of the compounds in it, made their own version of it and then sold that for a cheaper or price. stuart: that's not right. lauren: yeah. and it could be dangerous which is exactly what a eli lilly is saying. they're seeking injunctive orders and undisclosed damages. stuart: okay, next case. instacart, they ipo'd yesterday. they zoomed, and they were up 12% by the close. they're now down $1.87. lauren: they ipo field at 30 -- ipo'd opened at 30 and and went to 42. their enthusiasm is being challenged by, a, the competition and the difficulty of expanding their margins at a time when food prices are so high. food inflation, lots of competition. investors are evaluating that huge pop that they saw on day one, coming back down to earth. stuart: i see a downgrade for dollar general. lauren: yep

. >> shares of eli lilly rising today after a bullish call on the weight loss industry. emerging of obesity and diabetes drug market could grow to $100 billion just in the next seven years which could mean big gains for eli lilly diabetes drug, which is expected to be approved by regulars soon to treat obesity. that's why shares are up over 2%. shares of hard drive provider seagate going in the opposite direction, down over 10% right now. barclays downgrading the name, blaming poor fundamentals and recovery that could take longer than expected. separately, seagate just yesterday also announced plans to sell up to $1.5 billion in convertible notes in order to pay down debt. both of those contributing to the 10.5% drop. >> thank you. kristina partsinevelos. >>> the question of the day, we asked is apple's current valuation of 29 times forward earnings justified or not? yes, it is, or no, it's too expensive. the results after this break. >>> do not miss a cnbc exclusive interview, goldman sachs ceo david solomon sitting down with david faber 4:15 eastern during "overtime."

but i don't think they're going ruin the story for travis kelce or eli lilly which means you might bet them at a discount. most leagues offer an active roster spot for the flex position. given that it's not a real football position, just a construction of the fantasy football ecosystem, your goal is simple. get points however you can. you don't care if those points come from rushing, receiving or kick returns. you just want points from your flex. in terms of the stock market, i'll fill the flex spot with salesforce. i think it's a good fit because the value proposition here is changed dramatically, even in just the past year. for nearly two decades, salesforce was an unstoppable tusher charged growth stock that traded on revenue growth. but when the fed started raising interest rates last year, salesforce and the cloud software compadres were crushed because wall street suddenly cared about profitability. eventually with the statement late last year, a bunch of activist investors crowded into the stock over the unified message. they wanted the company to accelerate its long plan pivot

. >>> eli lilly is suing for selling selling non-fda approved versions of a drug >>> and the best timee best weight loss results >>> and amazon updating the cashless checkout to include clothing they would charge shoppers' carts when they walk out of store with inttheir items. >>> we hear from the actress who beat the clock to go from understud tee broadway leading lady, after this '6 , after this '6 [stomach growling] it's nothing... sounds like something. ♪when you have nausea, heartburn, indigestion♪ ♪upset stomach, diarrhea♪ pepto bismol coats and soothes for fast relief when you need it most. febreze! hate it when a car freshener hits you with an overwhelming blast of perfume? febreze car vent clips work differently. febreze gives you consistent freshness that starts just right and stays just right... ...for 40 days. upgrade to febreze car. ♪ there's one juice that can satisfy that savory craving, and get you your veggies. there's only one v8. oh... stuffed up again? so congested! you need sinex saline from vicks. just sinex, breathe, ahhhh! what is — wow! sinex. breathe. ahhhhhh!

so, ben, novo nordisk, eli lilly standing to make literally hundreds of billions of dollars on this.ock right now? >> i would have said it was until about a week ago, and novo nordisk had become the most valuable stock in europe. lilly is up a ton. both stocks have pulled back, and if you're the kind who likes to buy the dip and a momentum investor, probably would be a pretty decent time to go in and pick these up. but if you're thinking very long term the, i think you have to worry that a lot of the good news is priced into these stocks at this point. you hear analysts talk about really being only two stocks in pharma that you can own and that's novo and lilly, and i think at some point you do have to worry about competitors, prices under pressure a little bit and maybe just not as profitable as a people think, and then the stocks would be priced kind of to perfection. jack: got it. >> you would think that the health insurance stocks might get hit. they have not been. jack: and they probably figure if they do cover it, they'll just pass the prices on to the rest or of us. >> maybe.

bio scientists, merck, eli lilly and pharmaceuticals all provided support for us to come together here on this topic. and last i am pleased to acknowledge the national health council research program staff who've done an incredible job planning this event and coordinating an amazing series of speakers to explore critical topics on digital health and the science of patient engagement and they are doctor omar, lillian and karen. so let me say this with sincere gratitude that all of the national health council has engaged in today's discussion. i look forward to speaking with you today. and at the reception at 4:30 tonight. where he assured me there will be more discussion, great food and a lot of networking opportunities. so with that let me call on doctor omar the national health council senior vice president of equity, research program to discuss our agenda and keep us going. thank you. thank you all. [applause] >> good morning everyone and thank you, randy. i would like to begin by acknowledging the land which we stand first every committee owns a vitality to generations from around t

i will point out eli lilly shares are up in this market, up 51% this year, $525 billion market value> i asked all the execs in the so-called junk food category whether they'll get hurt they alwayssay the same thing. there's a lot of people who just like junk food that's true. alcohol has had this right now >> medtronic, you can almost see where these drugs began to get marketed >> that's true if you look at e.w. which is recommended today. that's when you have to have your chest cracked open -- you don't have to crack the chest cavity to use ew i thought that was a good upgrade this morning it's down 2 -- >> these drugs could have a positive impact on the health care environment if people have fewer heart attacks, fewer everything. >> you're saying wegovy, mounjaro. >> you're say thoog and combination of chatgpt has basically made it so nothing happens. everything is done by the machines we don't even eat. >> we're going to be like the people in wally. >> the only thing -- >> we won't be fat. >> the only thing that tastes good with that ozempic soil and cream. >> soil and cream. >> i

eli lilly does with mongorno. which is why the trust owns a huge amount of eli lilly. i will say the studies going on are far wider than obesity and far wider than diabetes. those considered heavy drinkers, which is two drinks a ight. there will be studies on smoking. there will be studies on what it does with the copd. now, the one thing i think people have to recognize is the insurance companies i think will end up paying for it because it is so revolutionary and it gets your bhlood pressure down. can downside is all the stuff you liked. i don't know if we have the charter. this is a chart of wegovi upside down. there is a note this morning. they're way behind on this. there is a piece about nestle's saying people are eating less, they're wasting less. no. people are taking wegovi. there is a sense of unworldliness among the snack food people who never saw that you can't eat one. not just one but one. >> yep. nope. it's -- the impact of these drugs we have yet to fully appreciate. by the way, again, there are certain things. listen, there are side effects. older peop

we could easily become a eli lilly fund. but we try to do we do not swing from one company.nd management. if you can avoid something just like that, it favors trimming, even if it is a great company. >> there is always that somewhere. am trying to find that for to f see you next time. >> right now on last call. he speaks and investors listen in. if it's friday, it's time for insider buys and big companies are making major moves. we will show them to you. times of changing leaves, football and government shutdowns? return to the office reckoning will businesses succeed with a aggressive post labor day sees? california utopia, the city fact

target and smucker all hovering near 52-week lows near something that hasn't happened in a while and eli lillyn musk denying the report that the company is in early talks to build an ev factory in saudi arabia and this comes a day after president erdogan invited him to build his next factory in that country. so what does the road look like for tesla? let's bring in cathie wood and tesla is her number one holding. thank you for being on fast. >> happy to be with you, melissa. thank you for inviting me. >> the traders at the desk were talking about tesla and your bear take for tesla is $1400 guy here said he'll take 1400 because that's still bullish >> what's in what assumptions are made about its business to get to that 1400 by '27 number? >> well, about a third of our valuation is associated with electric vehicles, evs and scaling them and as you mentioned, turkey, a plant there and many countries do want a tesla plant because this is the new world, right so that's good this is all working out and then two-thirds of our valuation is around autonomous, and autonomous platforms and we think tesl

eli lilly makes a similar medicine. it too is trying to expand its capacity.and out there for these medicines is just staggering. they are trying to keep up. boris? >> just scratching the surface, as he said. meg tirrell, thanks so much for the reporting. brianna? >>> the spanish women's soccer team coach is out. as the scandals surrounding the team's leadership grow and the new coach who was just announced is making history. we'll have details next. your record label is taking off. but so is your sound engineer. you need to hire. i need indeed. indeed you do. indeed instant match itantly delivers quality candidates matching your job descption. visit indeed.com/hire right now get a free footlong at subway. like the subway series menu. buy one footlong in the app, get one free. for freeee. that's what i'm talking about. order in the subway app today. and mine's unlisted. try boost® high protein with 20 grams of protein for muscle health versus 16 grams in ensure® high protein. boost® high protein. now available in cinnabon® bakery-inspired flavor. learn more at

jackie: this is much cheaper than the american eli lilly. this is danish company.harles: got the big gap. got up here. use this pull back as a opportunity to buy the stock on weakness? >> if you want to get in earnings potential and growth looks phenomenal. supply chain issues seem to be resolved this might be the entry point. charles: it is absolutely amazing. i do a piece on this, side-effects kidney failure, liver failure, we don't care. if we can eat and be slim, are you kidding me? are have you looked at economy about this you take this out economy is flat. >> this is driving denmark now. charles: you make a bet that americans will keep eating keep getting fat, having a miracle drug? >> as long as supply chain issues are out of i think this can continue. charles: wait this whole other thing, market malaise thing, wait it out. >> exactly, until we really understand where the bond yields are going it has been a sharp rise. you have to sort of reset. charles: right. >> for at that time least the next two to three weeks we'll have a reset. it will be very risky. i

volatile -- nvidia's in there, you've got apple, nike, microsoft and then you've got visa, mastercard, eli lilly names. i would think that way you keep your toe dip in some type of equity exposure. >> yeah. so the thought process behind that is that as we slow down and, again, this is not a recession call, but this is just a view that q4 is going to be a slower growth environment than q3. and in that environment where we're all so super focused on inflation data, on the growth data, on the consumer data as a you were pointing out, on whether or not the government shuts down, we think that in this volatile environment it is important to look at companies that have high cash flow, that have strong profitability and, very importantly, low debt. higher for longer, low leverage. liz les you've got an etf that that has the word buffer in it, okay? [laughter] it's the ivv, it's relatively new. >> it is. liz: and the promise, because i really looked deep into it, it's designed to prove 100% protection against stock market losses. 100%? [laughter] >> yeah. are. liz: right now it's flat, so you're looking

eli lilly and novo nordisk hitting highs today, as the popularity of weight loss drugs boosts the groupflaw with its engines will result in a $3 billion charge this quarter. the stock falling to its lowest level in over two years. and another down day for bitcoin. briefly dipping below 25,000 for the first time since june. >>> qualcomm shares jumping almost 4% today. chip maker extending its agreement with apple to provide 5g modems for smart phones into 2026. this as apple is set to unveil the iphone 15 tomorrow, which will reportedly have usb-c charging ports. big deal for qualcomm. that was always a question mark. >> yes, it's a big deal. the stock has been hammered over the last -- you look at the last six, nine months, down significantly. you think an announcement like this, given their valuation, this stock is up easy 5%, 10%. i don't think it's a particularly good performance, so, good for qualcomm, but we've learned historically, it's great to say apple's a client, blah, blah, apple has a way of squeezing their suppliers. >> yeah, 22% customer, so, it's important. and a lot of f

. >> caller: i have owned eel eli lilly for about six months and have done very well, pending approvaly has retreated from its $600 high by about $30. my question is should i hold it? sell it, or buy more on the dip? >> i always play with an open hand. we at the charitable trust sold some. we felt we weren't being disciplined. we were just letting it run. that's not the way i like to do things. that's what i teach at the club. that's what i'll teach tomorrow at noon. you cannot be greedy. we were being greedy. we took some off the table. in a tricky market, you have to have something to fall back on. these huge buybacks can given a terrific cushion, providing the underlying companies are actually worth investing. somebody asked me about autozone, up 100 today. that's all buyback. much more "mad money" ahead, including my exclusive with another i like, wingstop. after reporting another strong quarter last month, i'm seeing what's keeping this restaurant chain flying high with the company's ceo. >>> and what does barbra streisand's song "people" have to do with a thesis currently playing

those stocks eli lilly and novo nordisk. so as you're kind of tour of the headlines today. if i remember right with those originally out to treat diabetes and then it was discovered they had these weight loss benefits and now they're looking for other. >> benefits, i guess of this of these drugs. >> yeah. and you know, be honest. how keen 15 last year went from kind of proper 8. a little pudgy again, i'm thinking about it because i don't have a heart attack. yeah, i'm and i'm at the age for my dad. had a heart so it's kind of like maybe i should wake up and consider these not vanity drugs, right? but lifesaving drugs by saying it will care for not cheap. yeah, out. >> alright, next story. let's talk about tesla. just check their stocks off just a little bit this morning. not bad, but what's this word that they're going to be installing? what the thousands of their chargers at what hilton's across the country. >> yeah. north america and mexico and united states 2000 health and they're going to get 20,000 chargers. this is really good can now use the tesla chargers for all el

you can substitute hunger with self loathing. [ laughter ] and finally, the pharmaceutical company eli lilly today that it will cap the out of pocket cost of insulin at $35, and not a moment too soon [ laughter ] and that was the monologue we're off and running. [ cheers and applause we got a fantastic show for you tonight. he's a wonderful actor and a comedian who is currently out on his "dark pale" comedy tour. he's also starring in the new film, "linoleum," which is out now. jim gaffigan is back, everybody. [ cheers and applause and you know him from "mad about you," "curb your enthusiasm," "inside out," and too many hilarious roles to count he stars in "east new york," which airs sunday nights on cbs. our friend, richard kind, is back and joining us. [ cheers and applause but, before we get to all that, damning new details have been revealed from the billion dollar defamation lawsuit against fox news for spreading the baseless conspiracy theory that the 2020 election was rigged against donald trump including an admission from fox boss rupert murdoch that the networks hosts endorsed that

tomorrow's big fed decision, or not the dow falling 100 points the s&p and nasdaq dropping about 0.2% eli lilly. the drug maker accusing businesses of selling products claiming to contain terepatide -- >> sounds good to me >> go with it. >> own it, ty. >> own it. the active ungradient in the diabetes drug mounjaro, which is expected to be approved for weight loss later this year. eli shares are up 57% this year. mounjaro a big, big reason why >>> meantime, intel shares dropping as its innovation event kicks off. the recently outperforming semiposting its worst day since june the ceo speaking with cnbc about some big hardware announcements. kristina partsinevelos has more on the call and all of it. kristina >> well, he actually started the event with some push-ups on stage and afterwards, he proceeded to give a demonstration on a laptop and create a taylor swift-like song. the point of that is, i know everybody is distracted by the video, but the point of demonstrating with the laptop is that intel wants to bring a.i. to pcs that was the big message with this latest innovation, more of a develop

restoration act at the state level was the threat of economic destruction by companies like apple and eli lilly and the ncaa. a not even a not even a corporation that in a sense, forced indiana to reverse what was a legitimate piece of democratic legislation duly by the state legislature of a sovereign state of indiana and signed into law by then governor mike pence. and i hear none of my colleagues who constantly talk, endlessly about the threats to democracy faced by contemporary america when speaking of january six, have a peep say about the role that these private corporations played in, overturning a piece of state legislation. this is where i would say i don't want government to be around. i want government to do something in those kinds of situations. it needs to actually get out of the water, get out of the bath and do something and protect protect the citizens of that state. nor do i want the government doing everything in our lives. of course not. but this is where i think we need adequate prudence in judgment to determine where the right level of government should apply. the solomon

i think phaupb skwroer yo from eli lilly, i think you will see a lot of people start on that drug as., and there are other kinds of formulations come into the market. there are triple gs also implicated in the same pathway, and they look to have more efficacy with fewer side effects. >> when do you think we will see the oral drugs in a meaningful way? when does that hit the market? any sense of timing wise? >> well, my guess is these are 2025 events, so late 2024 events, and i am not sure of the time wise, and there's currently raw bell sus on the market, and you can't achieve the same dosage levels to get weight loss, and the drugs for diabetes, they use four times that dose for the weight loss indications, so you are taking a much higher dose to achieve the weight loss. >> a lot of people are not talking about it as a weight loss drug but an addiction avoidance drug, and folks that may not be overweight or obese are going to start taking the drugs, and somebody said to me the other day, we are going to be microdosing some version of the drug? >> yeah, there are two questions. is th